| Autor: |
Quick AM; Department of Radiation Oncology, The Ohio State University Medical Center, Columbus, OH 43210, USA., Hundley A; Department of Obstetrics and Gynecology, The Ohio State University Medical Center, Columbus, OH 43210, USA., Evans C; Department of Obstetrics and Gynecology, The Ohio State University Medical Center, Columbus, OH 43210, USA., Stephens JA; The Ohio State University Center for Biostatistics, Columbus, OH 43210, USA., Ramaswamy B; Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH 43210, USA., Reinbolt RE; Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH 43210, USA., Noonan AM; Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH 43210, USA., Van Deusen JB; Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH 43210, USA., Wesolowski R; Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH 43210, USA., Stover DG; Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH 43210, USA., Williams NO; Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH 43210, USA., Sardesai SD; Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH 43210, USA., Faubion SS; Department of Medicine, Mayo Clinic, Jacksonville, FL 32256, USA., Loprinzi CL; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA., Lustberg MB; Division of Medical Oncology Yale Cancer Center, New Haven, CT 06520, USA. |
| Abstrakt: |
(1) Background: The objective of this study was to determine the long-term efficacy of fractional CO 2 laser therapy in breast cancer survivors. (2) Methods: This was a single-arm study of breast cancer survivors. Participants received three treatments of fractional CO 2 laser therapy and returned for a 4 week follow-up. Participants were contacted for follow-up at annual intervals. The Vaginal Assessment Scale (VAS), the Female Sexual Function Index (FSFI), the Female Sexual Distress Scare Revised (FSDS-R), the Urinary Distress Inventory (UDI), and adverse events were collected and reported for the two-year follow-up. The changes in scores were compared between the four-week and two-year and the one-year and two-year follow-ups using paired t -tests. (3) Results: In total, 67 BC survivors were enrolled, 59 completed treatments and the four week follow-up, 39 participated in the one-year follow-up, and 33 participated in the two-year follow-up. After initial improvement in the VAS from baseline to the four week follow-up, there was no statistically significant difference in the VAS score (mean Δ 0.23; 95% CI [-0.05, 0.51], p = 0.150) between the four week follow-up and the two-year follow-up. At the two-year follow-up, the FSFI and FSDS-R scores remained improved from baseline and there was no statistically significant change in the FSFI score (mean Δ -0.83; 95% CI [-3.07, 2.38] p = 0.794) or the FSDS-R score (mean Δ -2.85; 95% CI [-1.88, 7.59] p = 0.227) from the one to two-year follow-up. The UDI scores approached baseline at the two-year follow-up; however, the change between the one- and two-year follow-ups was not statistically significant (mean Δ 4.76; 95% CI [-1.89, 11.41], p = 0.15). (4) Conclusions: Breast cancer survivors treated with fractional CO 2 laser therapy have sustained improvement in sexual function two years after treatment completion, suggesting potential long-term benefit. |
